Ua hoʻolaha ʻo Creative Medical Technology Holdings, Inc. i kēia lā ua kau inoa ʻo ia i kahi kuʻikahi me Cervos Inc. e lilo i mea hoʻolaha kūʻokoʻa o nā polokalamu Marrow Cellution™ no ka hoʻohana ʻana i ka urology, gynecology, a me ka male a me ka wahine.
"Ke hāʻawi nei kēia ʻaelike hoihoi iā mākou i ke komo kūʻokoʻa i nā polokalamu maikaʻi loa o Cervos Medical no ka hoʻohana ʻana i kekahi o kā mākou kī nui o ka autologous therapies, me ka CaverStem® no ka erectile dysfunction, FemCelz® no ka wahine maʻi wahine a, ma ka hoʻomaka ʻana, OvaStem® no nā wahine e loaʻa ana i ka hemahema o ka ovarian, "wahi a Timothy Warbington, Pelekikena a Luna Nui o ka Hui. "Me ka hoʻolako ʻia o nā mea kiʻekiʻe kiʻekiʻe, ikaika a ākea IP, koʻikoʻi koʻikoʻi mua-neʻe maikaʻi, hoʻokumu ʻia nā KOL, a me nā mea maʻi ʻoluʻolu, ʻo Creative Medical Technology kahi moat ākea a maikaʻi ke kūlana no ka kūleʻa."
Ua hoʻohui ʻo Harlan Adler, Pelekikena o Cervos Medical, "Ua hauʻoli mākou i ka hoʻonui ʻana i kā mākou pilina me Creative Medical Technology ʻoiai lākou e hoʻomau nei i ka neʻe ʻana i ka mākeke lāʻau regenerative i mua a hōʻike i nā pono he nui i loaʻa i nā pūnaewele i loaʻa mai ka iwi o nā maʻi i ka hoʻomaikaʻi ʻana. ola."
He aha e lawe ʻia mai kēia ʻatikala:
- “This exciting agreement provides us with exclusive access to Cervos Medical’s best-in-class devices for use in several of our key rapid autologous therapies, including CaverStem® for erectile dysfunction, FemCelz® for female sexual dysfunction and, upon launch, OvaStem® for women suffering with premature ovarian failure,”.
- “With a guaranteed supply of high quality devices, strong and broad IP, critical first-mover advantages, established KOLs, and satisfied patients, Creative Medical Technology has a wide moat and is well positioned for success.
- Harlan Adler, President of Cervos Medical, added, “We are thrilled to expand our relationship with Creative Medical Technology as they continue to push the regenerative medicine market forward and showcase the many benefits that stem cells derived from patients’.
